8 May 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces a year-end business update ahead of its preliminary results for the year ended 31 March 2019, which will be announced on Thursday 11 July 2019.
11 April 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 11 April 2019 that, on the same day, the following purchases of the Company’s ordinary shares of 1p each (“Ordinary Shares”) were made by directors of the Company
ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market
ReNeuron will be presenting at the H.C. Wainwright & Co. global life sciences conference in London on April 9th, 2019.
Olav Hellebo, ReNeuron CEO will be presenting via webcast at the Alliance for Regenerative Medicine : Cell & Gene investor day on March 21, 2019.
ReNeuron’s slot is approximately 9.10am Eastern time (approx. 1.10 pm UK time)
To listen, please follow the link to access further information
18 March 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a further update on progress with the ongoing Phase I/II clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
